On January 14, 2020, Zhejiang Tailin Biotech Co., Ltd. rang the bell of listing at Shenzhen Stock Exchange to officially land at the GEM board, which meant that the first stock of Zhejiang in 2020 has arrived. It was also the 50th listed company of the Binjiang District in Hangzhou.

This time Tailin Biotech issued 13 million shares at a price of 18.35 yuan per share and an opening price of 24.22 yuan per share. By 9:35 am that day, its stock price rose to 26.42 yuan per share, with a total market value of 1.373 billion yuan.

It was another enterprise transferred from China's NEEQ (National Equities Exchange And Quotations). On August 17, 2015, Tailin Biotech was listed in the NEEQ. On June 20, 2016, it submitted an application for the public issuing of A-shares and going public to China Securities Regulatory Commission for the first time. On January 3, 2018, the first issuance of shares was approved by the company.

The company is mainly specialized in the research and development, manufacture and sales of microbiological detection and control technology system products, organic matter analysis instruments and other pharmaceutical equipment, which belongs to the industry of pharmaceutical manufacture. Its major clients include CR Shuanghe, Yunnan Baiyao, and Harbin Pharmaceutical.

Executive Editor: Ye Ke

Translation: Ye Ke, Chen Wenjing